Background/Aims: Diabetic retinopathy is associated with accumulation of advanced glycation end products (AGEs) in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. In the present study we have explored the role of LR-90 in the progression of experimental diabetic retinopathy.
Methods: Streptozotocin (STZ) induced diabetic Sprague-Dawley rats were treated with LR-90 (50mg/l in drinking water) for up to 32 weeks. At the end of the study eyes were enucleated and subjected to trypsin digestion and staining with light green-haematoxylin. Acellular capillaries and number of pericytes were quantified in random fields using light microscopy.
Results: In the LR-90 treated diabetic animals, acellular capillary numbers were reduced to 1.63 ± 0.20 from 2.58 ± 0.49 (p<0.05) in diabetic controls. Also, LR-90 treatment significantly restored pericyte deficit from 18.12 ± 0.98 in diabetic rats to 24.19 ± 0.76 (p<0.001) in the LR-90 treated group. Conclusion: These findings demonstrate that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in diabetic patients.
- Advanced Glycation End Products
- Diabetic retinopathy